Back to Browse Journals » International Journal of Nanomedicine » Volume 3 » Issue 2

Drug delivery and nanoparticles: Applications and hazards

Authors Wim H De Jong, Paul JA Borm

Published Date June 2008 Volume 2008:3(2) Pages 133—149

DOI http://dx.doi.org/10.2147/IJN.S596

Published 30 June 2008

Wim H De Jong1, Paul JA Borm2,3

1Laboratory for Toxicology, Pathology and Genetics, National Institute for Public Health and the Environment (RIVM), Bilthoven, The Netherlands; 2Zuyd University, Centre of Expertise in Life Sciences, Heerlen, The Netherlands; 3Magnamedics GmbH, Aachen, Germany

Abstract: The use of nanotechnology in medicine and more specifically drug delivery is set to spread rapidly. Currently many substances are under investigation for drug delivery and more specifically for cancer therapy. Interestingly pharmaceutical sciences are using nanoparticles to reduce toxicity and side effects of drugs and up to recently did not realize that carrier systems themselves may impose risks to the patient. The kind of hazards that are introduced by using nanoparticles for drug delivery are beyond that posed by conventional hazards imposed by chemicals in classical delivery matrices. For nanoparticles the knowledge on particle toxicity as obtained in inhalation toxicity shows the way how to investigate the potential hazards of nanoparticles. The toxicology of particulate matter differs from toxicology of substances as the composing chemical(s) may or may not be soluble in biological matrices, thus influencing greatly the potential exposure of various internal organs. This may vary from a rather high local exposure in the lungs and a low or neglectable exposure for other organ systems after inhalation. However, absorbed species may also influence the potential toxicity of the inhaled particles. For nanoparticles the situation is different as their size opens the potential for crossing the various biological barriers within the body. From a positive viewpoint, especially the potential to cross the blood brain barrier may open new ways for drug delivery into the brain. In addition, the nanosize also allows for access into the cell and various cellular compartments including the nucleus. A multitude of substances are currently under investigation for the preparation of nanoparticles for drug delivery, varying from biological substances like albumin, gelatine and phospholipids for liposomes, and more substances of a chemical nature like various polymers and solid metal containing nanoparticles. It is obvious that the potential interaction with tissues and cells, and the potential toxicity, greatly depends on the actual composition of the nanoparticle formulation. This paper provides an overview on some of the currently used systems for drug delivery. Besides the potential beneficial use also attention is drawn to the questions how we should proceed with the safety evaluation of the nanoparticle formulations for drug delivery. For such testing the lessons learned from particle toxicity as applied in inhalation toxicology may be of use. Although for pharmaceutical use the current requirements seem to be adequate to detect most of the adverse effects of nanoparticle formulations, it can not be expected that all aspects of nanoparticle toxicology will be detected. So, probably additional more specific testing would be needed.

Keywords: drug delivery, cancer therapy, nanoparticles, toxicology, pharmaceuticals

Download Article [PDF] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php

Readers of this article also read:

Fungus-mediated biological synthesis of gold nanoparticles: potential in detection of liver cancer

Chauhan A, Zubair S, Tufail S, Sherwani A, Sajid M, Raman SC, Azam A, Owais M

International Journal of Nanomedicine 2011, 6:2305-2319

Published Date: 12 October 2011

Benefit of intravenous antibiotic therapy in patients referred for treatment of neurologic Lyme disease

Stricker RB, DeLong AK, Green CL, Savely VR, Chamallas SN, Johnson L

International Journal of General Medicine 2011, 4:639-646

Published Date: 6 September 2011

Epigenomics in cancer management

Fabricio F Costa

Cancer Management and Research 2010, 2:255-265

Published Date: 27 October 2010

Baseline characteristics and initial treatment decisions for patients with schizophrenia at risk of treatment nonadherence

Katarina Kelin, Alan JM Brnabic, Richard Newton, et al

Patient Preference and Adherence 2010, 4:301-311

Published Date: 11 August 2010

Continuation treatment of major depressive disorder: is there a case for duloxetine?

Trevor R Norman, James S Olver

Drug Design, Development and Therapy 2010, 4:19-31

Published Date: 12 February 2010

Safety of etanercept in elderly subjects with rheumatoid arthritis

Alfredomaria Lurati, Mariagrazia Marrazza, Katia Angela, et al

Biologics: Targets and Therapy 2010, 4:1-4

Published Date: 22 December 2009

Acquired color vision and visual field defects in patients with ocular hypertension and early glaucoma

Dimitris Papaconstantinou, Ilias Georgalas, George Kalantzis, Efthimios Karmiris, et al.

Clinical Ophthalmology 2009, 3:251-257

Published Date: 13 March 2009

Nanoparticles and cancer therapy: A concise review with emphasis on dendrimers

Dhruba J Bharali, Marianne Khalil, Mujgan Gurbuz, Tessa M Simone, Shaker A Mousa

International Journal of Nanomedicine 2009, 4:1-7

Published Date: 20 January 2009

Applications of gold nanoparticles in cancer nanotechnology

Weibo Cai, Ting Gao, Hao Hong, Jiangtao Sun

Nanotechnology, Science and Applications 2008, 1:17-32

Published Date: 19 September 2008